GlassScriptPhysician profile
Elizabeth Miranda
NPI 1356870257
$853.23
in general payments reported to CMS, 2019-2025
24 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.08 · 2022: $75.10 · 2023: $121 · 2024: $352 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.00 | 2023-2025 | Xifaxan, Trulance |
| Abbvie INC. | $98.77 | 2022-2025 | |
| Mdd US Operations, LLC | $72.10 | 2023-2024 | Apokyn, Apokyn, Xadago |
| Lilly USA, LLC | $59.93 | 2024-2025 | Kisunla, Amyvid |
| Vanda Pharmaceuticals INC. | $51.08 | 2025 | Ponvory |
| Argenx US, INC. | $48.46 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $36.09 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $35.16 | 2024-2025 | Ultomiris |
| Ucb, INC. | $31.80 | 2023-2025 | Nayzilam, Briviact |
| Glaxosmithkline, LLC. | $28.44 | 2021-2022 | |
| Boston Scientific Corporation | $25.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.02 | 2024 | |
| Neurocrine Biosciences, INC. | $20.08 | 2025 | |
| Sk Life Science, INC. | $20.06 | 2025 | |
| Lundbeck LLC | $17.74 | 2024 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17.15 | 2023 | Sunosi |
| Acadia Pharmaceuticals INC | $16.65 | 2025 | Nuplazid |
| Impel Pharmaceuticals INC. | $16.55 | 2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $15.80 | 2024 | Rexulti |
| Neurelis, INC. | $15.60 | 2024 | Valtoco |
| Janssen Pharmaceuticals, INC | $15.00 | 2022 | |
| Hikma Pharmaceuticals USA | $13.80 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.64 | 2024 | Horizant |
| Aucta Pharmaceuticals, INC. | $12.11 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.